PROMISE Registry: PROspective Study on Management of Ischemic Stroke Secondary to mEvo Registry
Investigators are conducting a real world, observational, prospective, multicenter study to better understand treatment for patients with MeVo and distal vessel occlusions in the U.S post publication of recent MeVO trials.
• Acute ischemic stroke clinically eligible for immediate EVT
• Age ≥18 - 85 years of age
• Time from onset (or last-seen-well) to 24 hours
• Disabling stroke defined as follows:
• A. Baseline National Institutes of Health Stroke Scale (NIHSS) score \>5 B. Baseline NIHSS 3-5 with disabling deficit (e.g., hemianopia, aphasia, loss of hand function) as determined and agreed upon by two physicians in context of the patient's life
• Confirmed treatable MeVO based on neurovascular non-invasive imaging (CTA or MRA), at one or more of the following locations: M2 or M3 segment, A2 or A3 segment, P1, P2 or P3 segment
• Informed consent: Within the first 72 hours after inclusion in the study
• ASPECTS ≥5
• mRS≤2